刚刚，直线拉升！美国传来大消息！

Group 1 - The core viewpoint of the article highlights a significant rebound in the innovative drug sector in both A-shares and Hong Kong stocks, with notable stocks like Huaren Health and Seli Medical reaching their daily limit up [2] - The approval of the revised Biological Safety Act as part of the U.S. National Defense Authorization Act for fiscal year 2026 is expected to positively impact the industry, with the act not specifically naming any companies but indicating future management of restricted enterprises [3] - Analysts suggest that the passage of the 2025 legislation marks a phase of stabilization for the industry, allowing a return to long-term growth logic, particularly for leading companies like WuXi AppTec, which have shown strong performance despite previous market fluctuations [3][4] Group 2 - The CXO sector has seen improved valuation attractiveness following adjustments in Q4 2025, with expectations of continued upward trends in industry operations for 2026 [4] - External factors affecting the CXO industry, such as the U.S. Biological Safety Act and drug tariffs, are showing marginal improvement, leading to a more favorable sentiment and the beginning of a new high prosperity cycle driven by overseas interest rate cuts and domestic recovery [6] - The overall demand for CXO services is on the rise, with both order volumes and financing showing positive trends, indicating a robust recovery in the sector [6]